Cell line · CVCL_0179
BT-474
Cancer cell line, Homo sapiens. Invasive breast carcinoma of no special type. 172 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Cite this record
ConductScience Library. BT-474. Cell lines, record CVCL_0179. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_0179
On this page
Cell line
As Cellosaurus gives it.
- Name
- BT-474
- Accession
- CVCL_0179
- RRID
- RRID:CVCL_0179
- Synonyms
- Bt-474, BT474
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- 60Y
- Category
- Cancer cell line
- Diseases
- Invasive breast carcinoma of no special type (NCIt C4194)
- Derived from
- Breast (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2026-03-31
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers172
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Impact of Trastuzumab and Pertuzumab on HER2 Localization and the Estrogen Receptor Cistrome in ER+/HER2+ Breast Cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The role of autoproteolysis and mitoribosomal proteins in the regulation of the mitochondrial LACTB tumor suppressor. | EMBO Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting CD24 Activates Macrophages to Reduce Tumor Burden in Preclinical Models of Solid Tumors. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targetable S100-RAGE Signaling Mediates Intrinsic Trastuzumab Deruxtecan Resistance in Metastatic Breast Cancer. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Distinct metabolic dependency on BCAA defines cancer stemness and malignancy in human triple-negative breast cancer. | Cell Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Single-Cell and Multiomics Characterization of p21 in Cancer Progression and Therapeutic Sensitivity. | Hum Mutat | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Engineering Cathepsin S Selective Chemical Probes and Antibody-Drug Conjugates through Substrate Profiling with Unnatural Amino Acids. | J Med Chem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combined inhibition of PLK4 and PPM1D promotes cell death in cancer cells with 17q amplification. | Cancer Cell Int | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Hydrostatic pressure activates HIF-1α via β-catenin to promote stemness in breast cancer cells. | FEBS Open Bio | 2026 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 172
See all 172 papersRelatives15
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | BT-474 Clone 5 | CVCL_AQ07 | Cell lines | |
| Derived from it | BT-474 EEI | CVCL_AR96 | Cell lines | |
| Derived from it | BT-474 Ecadherin EmGFP | CVCL_A4CL | Cell lines | |
| Derived from it | BT-474 Tam1 | CVCL_AR86 | Cell lines | |
| Derived from it | BT-474 Tam2 | CVCL_A4AK | Cell lines | |
| Derived from it | BT-474-Luc2 | CVCL_C9CU | Cell lines | |
| Derived from it | BT-474/CMV-Luc | CVCL_4Y08 | Cell lines | |
| Derived from it | BT-474c1 | CVCL_IP20 | Cell lines | |
| Derived from it | BT474 A3 | CVCL_YX79 | Cell lines | |
| Derived from it | BT474-5FU[r] | CVCL_4V65 | Cell lines |
1 to 10 of 15
See all 15 relativesCell banks13
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CRL-7913 | Discontinued | Cellosaurus |
| ATCC | HTB-20 | ATCC | |
| AddexBio | C0006012/4902 | Cellosaurus | |
| BCRC | 60359 | BCRC | |
| BCRJ | 0353 | BCRJ | |
| CLS | 300131 | CLS | |
| DSMZ | ACC-64 | DSMZ | |
| Hysigen | TCH-C139 | Hysigen | |
| IBRC | C10140 | Cellosaurus | |
| ICLC | HTL00008 | ICLC |
1 to 10 of 13
See all 13 cell banksData dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0179
GET https://conductscience.org/api/cell-lines/v1/CVCL_0179/papers?page=2